Abstract. genomic instability and resistance to genotoxic therapies for glioblastoma (gBM) suggest aberrant DnA damage response (DDr), since DDr maintains the genomic integrity against genotoxic insults including anti-tumor therapies. to elucidate the biological and clinical meaning of DDr in gBM, we retrospectively investigated the immunohistochemical expression of DDr proteins (AtM, chk1, chk2, topBp1, rad17, p53, nbs1, MDc1, γH2AX and rpA1) in 69 gBM surgical samples and their relation with gBM patient survival. Remarkably, higher expression of ATM revealed significantly longer overall survival (os) and progression-free survival (pFs) (p<0.05). Upon multivariate analysis, expression level of AtM was an independent factor for longer os (p=0.020) and longer pFs (p=0.019). since AtM induces cell cycle arrest or apoptosis through cell cycle regulators in response to genotoxic insults, these results indicate that aberrant DDr signaling through AtM in gBM may be associated with resistance to genotoxic anti-tumor therapeutics. conclusively, we emphasize that the identification of DDr machinery, which can be involved in unstable genomic status or genotoxic therapies in gBM, is very important to predict patient outcome.
Introduction glioblastoma (gBM) is the most frequent and malignant human brain tumor with poor response to conventional genotoxic therapies (1) . the methylation status of o 6 -methylguanine-DnA methyltransferase (MGMT) and mutations of isocitrate dehydrogenase (IDH) genes have been identified as prognostic and/or predictive biological markers of gBM by comprehensive genetic analyses (2-4). However, the major huddles in treating these tumors still remain, leaving only genotoxic modalities such as radiation and chemotherapy as viable treatment options. to overcome these limitations, novel prognostic markers that could be utilized as therapeutic targets need to be elucidated further.
cellular DnA damage response (DDr) pathways induce cell cycle arrest and DnA repair in response to the DnA damage (5) (6) (7) . In many cancers, these DDr machineries are activated by oncogene-evoked replication stress (5, 6, 8) , which might suppress genomic injury induced by genotoxic anti-tumor therapies. therefore, the DDr machineries could be potential therapeutic targets to overcome the resistance to chemotherapy and radiotherapy in gBM (9, 13) . nonetheless, a clinical study on the expression of DDr and the prognostic implication in gBM has yet to be published.
to elucidate the biological and clinical meaning of the DDr pathway in gBM, we present immunohistochemical analyses of DDr or its related proteins such as ataxia telangietactasia mutated (AtM), checkpoint kinase 1 (chk1), checkpoint kinase 2 (chk2), topoisomerase binding protein 1 (topBp1), rad17, nijmegen breakage syndrome 1 (nbs1), mediator of DnA damage checkpoint 1 (MDc1), histone H2A isoform γ (γH2AX), replication protein A 1 (rpA1) and p53. We further report the correlation between the expression level of these components and patient survival.
Materials and methods
Patient and tissue collection. sixty-nine patients with gBMs were included in this study. Among them, adjacent normal brain tissues were included in 26 cases to compare the differential expressions between gBM and normal tissues. patient characteristics are summarized in sections were examined for immunoreactivity for the proteins by an observer who was unaware of the pathological diagnoses, outcomes or clinical features. tumors were categorized as follows: grade 0 for those expressing no protein, grade 1 for those expressing in <25% of cells, grade 2 for those expressing in 25-50% of cells at similar or overexpressed levels compared to the normal brain, grade 3 for those in 50-75% of cells and grade 4 for those in >75% of cells, based on the expression level in nucleus visualized in a high-power field in areas with maximal staining. The expression of the proteins was analyzed as a dichotomous covariate: no or little immunoreactivity (grade 0 or 1) vs. overexpression (grades 2-4).
Bisulfite modification and methylation-specific PCR. DnA (1 µg) from the tumor was denatured by sodium hydroxide and modified by sodium bisulfite. Methylation-specific pcr was performed as previously described (14) .
Cell culture and cell lines. Human glioma cell lines, U138Mg, U373Mg, U87Mg, U251Mg and control human osteosarcoma cells (U2os) (American type culture collection) were maintained in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% fetal bovine serum (Hyclone laboratories, Inc., logan, Ut, UsA), 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were cultured in a 37˚C, 5% CO 2 humidified chamber.
Ionizing radiation and Western blotting. cells were lysed and prepared for Western blot analysis as previously described (15) . cells were processed 6 h after ionizing radiation (Ir) (10 gy), washed (pBs) and harvested. Anti-AtM, -Atr, -chk1 anti- bodies were purchased from santa cruz Biotechnology (santa cruz Biotechnology). Anti-topBp1 and -MDc1 were obtained from Bethyl laboratoratoies. Anti-human α-tubulin antibody was from oncogene research products (cambridge).
Statistical analysis. the comparison of expression levels between tumors and adjacent normal brain was analyzed by paired sample t-test. the analysis of the relation between the above protein expressions and overall or progression-free survival was investigated by using the Kaplan-Meier method (spss statistical software, version 18.0; spss Inc., chicago, Il, UsA). the differences between the survival curves were tested using the log-rank test. the correlation among the variables was analyzed by Spearman correlation coefficient. (Fig. 1a) . the median progression-free survival was 204 (95% cI, 180-227) days (Fig. 1b) . other demographic data are described in table I. Univariate analysis of possible prognostic factors revealed several meaningful results that were related to overall survival (os) or progression-free survival (pFs) (table II, Fig. 1a and b) . Age factor showed borderline significance as follows: patients >70 years of age (n=7) showed lower median survival than those ≤70 years of age (n=62) (p=0.055, Fig. 1c) . However, the factor was not found to be correlated with pFs (p=0.948). gender, preoperative Karnofsky performance status (Kps), and the methylation status of MgMt were not correlated with patient os or pFs (table II) . solitary tumors (n=52) showed significantly longer OS than multiple tumors (n=17) (p<0.001, Fig. 1d ). In addition, total resection (n=51) revealed better os than partial resection or biopsy (n=18) (p=0.006, Fig. 1e) .
Expression of components of the DDR pathway in GBM.
expression of 10 DDr-related proteins (AtM, chk1, chk2, topBp1, rad17, p53, nbs1, MDc1, γH2AX and rpA1) was analyzed immunohistochemically. expression level of each protein was categorized as follows: grade 0 for those expressing no protein, grade 1 for those expressing in <25% of cells, grade 2 for those expressing in 25-50% of cells, grade 3 for those in 50-75% of cells and grade 4 for those in >75% of cells.
At first, alteration in the expression of the 10 DDR-related proteins in gBM was analyzed using 26 gBM and paired adjacent normal brain samples. expression of all the 10 DDr-related proteins was increased in gBM compared with relatively normal brain (table III) . especially, AtM, chk1, chk2, topBp1, p53 and nbs1 were overexpressed significantly in GBMs (p<0.05, Table III ). Therefore, expression of components of the DDr pathway is maintained or increased in gBM.
Clinical and prognostic implications of the DDR pathway in GBM.
To find out the clinical implication of increased expression of the DDR pathway, 69 GBM patients were classified into two groups for each DDr-related protein; no or little immunoreactivity (grade 0 or 1) vs. overexpression (grades 2-4) (table II). When os and pFs were compared between the two groups for each DDr-related protein by univariate analysis, the expression of ATM showed significant correlation with both os and pFs of the patients (p=0.048 and 0.029, respectively, table II, Fig. 1f ). Higher expression level of this protein revealed longer survival. Higher expression of p53 was also associated with longer pFs (p=0.004). other DDr proteins were not correlated with os or pFs, although borderline significance was observed with topBp1 in os (p=0.076).
on multivariate analysis (table IV) , age >70 years and presence of multiple masses were significant prognostic factors of poor os (p=0.037 and 0.000, in each). remarkably, higher expression of AtM was a significant independent factor for longer os (p=0.020, table IV). For longer pFs, the increased expression of AtM and p53 were independent prognostic factors (p=0.019 and 0.011, respectively, table IV) confirming prognostic significance of expression of ATM in gBM.
Correlation of expression between cell cycle regulators and ATM. since DDr pathways induce cell cycle arrest in response to DnA damage (5-7), AtM overexpression in gBM might be related with the alteration in the regulatory mechanism of cell cycle. therefore, p21, p27, p18 and MDM2 were additionally immunostained in 69 gBM patients, expression level of each protein was categorized using the same method with DDr proteins, and correlation with AtM expression was analyzed. The Spearman correlation coefficients (p-value) are as following: p53, 0.244 (0.043); p27, 0.339 (0.006); p21, 0.240 (0.056); p18, 0.107 (0.398); and MDM2, 0.213 (0.086). resultantly, expression level of AtM was positively correlated with that of p53, p27 and p21. the representative IHc results of correlation among AtM, p53, p21 and p27 are presented in Fig. 2 .
results in this study indicate that maintained or increased expression of AtM and related cell cycle regulators suggest better clinical outcomes of gBM patients (os and pFs). since AtM induces cell cycle arrest or apoptosis in response to genotoxic insults such as irradiation, these results also indicate that maintained signaling through AtM and downstream cell cycle regulator might be needed for therapeutic effects of genotoxic anti-tumor modalities.
Alteration in ATM expression of glioma cells in response to irradiation.
In the response to DnA damage, several component of DDr pathway such as AtM, Atr, MDc1, topBp1 and chk1 are involved in the initiation of signaling.
Above results indicate that AtM could be the major initiator of signaling and induce cell cycle arrest and/or apoptosis in response to genotoxic insults in gBM. We analyze alteration in the expression levels of DDr proteins (AtM, Atr, MDc1, topBp1 and chk1) in glioma cell lines (U138Mg, U373Mg, U87Mg, U251Mg) and U2os, 6 h after 10 gy in vitro irradation (Fig. 3) . the cell lines showed varying degrees of basal expression for AtM, Atr, MDc1, topBp1 and chk1. the level of expression was similar or slightly increased after in vitro irradation. However, interestingly, the expression of AtM was increased after irradiation in U138Mg and U251Mg. these data suggest that AtM and its downstream signaling components affected the response to irradiation in gBM.
Discussion
numerous studies have revealed cascades of DDr after DnA damage such as Ir or genotoxic therapies (16, 19) . However, they have been mainly focused on the signal pathway and molecular interactions. there has been no report suggesting the clinical implication of DDr in gBM. therefore, we performed this study to examine the prognostic meaning of DDr in gBM. In this study, the samples were mostly removed before radiation or chemotherapy. the expression of DDr proteins including AtM was higher in tumor samples than in their adjacent normal samples. thus, these results indicated that the DDr machinery became activated because of some aberrant, stressful endogenous processes that threaten the genomic integrity and/or occur during the constitutive development of gBM (5, 7) . In this study, AtM was revealed to be an independent prognostic factor related to longer os and pFs. p53 was also related to longer pFs. Higher expression of topBp1, which is a direct activator of Atr (20) and a connector of ATM to ATR (17) , revealed borderline significance for longer os. In addition, we showed that the expression level of AtM was positively correlated with that of p27 and p21 as well as p53. since DDr pathways are related with the alteration in the regulatory mechanism of cell cycle (5-7), the tumor suppressors p21 and p27 might be functionally-correlated with p53 in many cancers (21) . Moreover, increased p21, which is a downstream protein of p53, is thought to be an indicator of intact p53 (21, 22) . there are many studies suggesting that lower expression of p27 and p21 could be a negative prognostic marker in various cancers (23) (24) (25) . therefore, our positive prognostic results of AtM expression in conjunction with tumor suppressor genes such as p53, p21 and p27 might be explained in gBMs.
DDr machinery including AtM is thought to be a barrier against glioma progression, because it may limit the expansion of nascent malignant clones with unstable genome (5, 6) . Furthermore, gilbert and Hemann (26) suggested AtM inhibition could result in increasing secretion of cytokines such as Il-6, which is an important factor secreted from the endothelial cells around chemoresistant niche. It may also explain the role of AtM for increasing efficacy of genotoxic therapies in some tumors. on the other hand, some researchers have suggested the possibility of DnA damage checkpoints or repair inhibitors for radiosensitizing in glioma therapies (9) (10) (11) (12) (13) (27) (28) (29) . their experimental data suggested DDr machinery could be a target to overcome the resistance to chemotherapy and radiotherapy in gBM, because DnA repair systems were transiently inhibited after administration of inhibitors for DDr.
on the basis of our clinical analysis in conjunction with previous reports (1, 5, 6) , further clinical trials targeting DDr in gBM should be very cautiously approached. It is because DDr can be a continuous defensive process even in malignant tumors, which might be a reflection of favorable outcome. In addition, maintaining the DDr signaling through AtM and downstream cell cycle regulator might be needed for therapeutic effects of genotoxic anti-tumor modalities, considering the original role of AtM for cell cycle arrest or apoptosis. even though further larger scaled studies are needed, we emphasize that the identification of DDR machinery, which can be involved in unstable genomic status or genotoxic therapies in gBM, is very important to predict patient outcome.
